Drug Combo Improves Performance Of Multiple Sclerosis Drug
Published: March 17, 2006
The performance of the currently used multiple sclerosis drugs can be enhanced by statin therapy, report a group of researchers . Previously, the same group of researchers had established that stain drugs used for lowering of cholesterol could lower the development of full-blown form of multiple sclerosis.
Although the following results have only been documented in animal models of the disease, so far, the researchers hope that the findings could one day revolutionize treatment of multiple sclerosis, in humans. The results of this promising study can be found in the latest issue of the Journal of Clinical Investigation.
Multiple Sclerosis results from an immune system disorder in which the immune cells attack the myelin sheath (an insulation layer) present in nerve fibers around the spinal cord and brain. Treatment of the disease is based on the use of drugs (Copaxone) that selectively inhibits the destruction of myelin. Copaxone treatment however is effective only in about 30- 35% of the cases.
The researchers, inspired by results of their first study, set out to explore the effectiveness of the new drug combination, Copaxone- Atorvastatin. Addition of high doses of the cholesterol-lowering drug was found to produce a drastic reduction in the inflammation of the central nervous system and elimination of paralysis in animal models designed to mimic human models of MS.
If you enjoyed this good news Subscribe to Good News Blog
Share this
To share this simply copy and paste one of the below URL's: